Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP

Journal of Neurochemistry

Volumn 104, Issue 5, 2008, Pages 1309-1320

  Samantaray, Supriti ^a   Knaryan, Varduhi H ^b   Butler, Jonathan T ^a   Ray, Swapan K ^a   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

Author keywords

Dopamine transporter; Experimental parkinsonism; Monoamine oxidase B; MPP +; Parkinson's disease; Spinal cord

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; KYNURAMINE; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROFLUOROMETRY; SPINAL CORD ATROPHY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; LUMBAR VERTEBRAE; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NERVE DEGENERATION; PARKINSON DISEASE, SECONDARY; SPINAL CORD DISEASES;

MUS;

EID: 39749140228     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05091.x     Document Type: Article

References (64)

1. Battaglia G., Busceti C. L., Molinaro G., Biagioni F., Storto M., Fornai F., Nicoletti F. Bruno V. (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 24, 828 835.
2. Beyer M. K., Janvin C. C., Larsen J. P. Aarsland D. (2007) A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry 78, 254 259.
3. Bezard E., Gross C. E., Fournier M. C., Dovero S., Bloch B. Jaber M. (1999) Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155, 268 273.
4. Bloch A., Probst A., Bissig H., Adams H. Tolnay M. (2006) α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol. 32, 284 295.
5. Braak H., Del Tredici K., Rub U., de Vos R. A., Jansen Steur E. N. Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197 211.
6. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M. Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 80, 4546 4550.
7. Cardellach F., Marti M. J., Fernandez-Sola J., Marin C., Hoek J. B., Tolosa E. Urbano-Marquez A. (1993) Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43, 2258 2262.
8. Chera B., Schaecher K. E., Rocchini A., Imam S. Z., Ray S. K., Ali S. F. Banik N. L. (2002) Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. Ann. NY Acad. Sci. 965, 274 280.
9. Chera B., Schaecher K. E., Rocchini A., Imam S. Z., Sribnick E. A., Ray S. K., Ali S. F. Banik N. L. (2004) Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-treated mice. Brain Res. 1006, 150 156.
10. Chiba K., Trevor A. Castagnoli Jr. N. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574 578.
11. Chiueh C. C., Markey S. P., Burns R. S., Johannessen J. N., Pert A. Kopin I. J. (1984) Neurochemical and behavioral effects of systemic and intranigral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur. J. Pharmacol. 100, 189 194.
12. Crocker S. J., Smith P. D., Jackson-Lewis V. et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23, 4081 4091.
13. Dauer W. Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889 909.
14. Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Reichert C. M. Kopin I. J. (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1, 249 254.
15. Giovanni A., Sieber B. A., Heikkila R. E. Sonsalla P. K. (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257, 691 697.
16. Giovanni A., Sieber B. A., Heikkila R. E. Sonsalla P. K. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Part 1: Systemic administration. J. Pharmacol. Exp. Ther. 270, 1000 1007.
17. Goedert M. (2001) α-Synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492 501.
18. Haas R. H., Nasirian F., Nakano K., Ward D., Pay M., Hill R. Shults C. W. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37, 714 722.
19. Haber S. N., Ryoo H., Cox C. Lu W. (1995) Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362, 400 410.
20. Hallman H., Olson L. Jonsson G. (1984) Neurotoxicity of the meperidine analogue 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur. J. Pharmacol. 97, 133 136.
21. Hammock B. D., Beale A. M., Work T., Gee S. J., Gunther R., Higgins R. J., Shinka T. Castagnoli Jr. N. (1989) A sheep model for MPTP induced Parkinson-like symptoms. Life Sci. 45, 1601 1608.
22. Hersch S. M., Yi H., Heilman C. J., Edwards R. H. Levey A. I. (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 388, 211 227.
23. Holstege J. C., Van Dijken H., Buijs R. M., Goedknegt H., Gosens T. Bongers C. M. (1996) Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord. J. Comp. Neurol. 376, 631 652.
24. Hwang J. J., Liao M. H., Yen T. C., Wey S. P., Lin K. J., Pan W. H., Chen J. C. Ting G. (2002) Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography. Appl. Radiat. Isot. 57, 35 42.
25. Inoue H., Castagnoli K., Van Der Schyf C., Mabic S., Igarashi K. Castagnoli Jr. N. (1999) Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives. J. Pharmacol. Exp. Ther. 291, 856 864.
26. Jackson-Lewis V. Przedborski S. (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2, 141 151.
27. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol. 106, 455 456.
28. Judith J. A., D'Amato R. J., Strittmatter S. M. Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite 1-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. USA 82, 2173 2177.
29. +: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic. Biol. Med. 15, 169 179.
30. Klos K. J., Ahlskog J. E., Josephs K. A., Apaydin H., Parisi J. E., Boeve B. F., DeLucia M. W. Dickson D. W. (2006) α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66, 1100 1102.
31. Langston J. W., Ballard P., Tetrud J. W. Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979 980.
32. Liu Y., Roghani A. Edwards R. H. (1992) Gene transfer of a reserpine-sensitive mechanism of resistance to 1-methyl-4-phenylpyridinium. Proc. Natl Acad. Sci. USA 89, 9074 9078.
33. Lyden A., Bondesson U., Larsson B. S., Lindquist N. G. Olsson L. I. (1985) Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues. Acta Pharmacol. Toxicol. (Copenh) 57, 130 135.
34. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S. Herkenham M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464 467.
35. Martin L. J., Pan Y., Price A. C., Sterling W., Copeland N. G., Jenkins N. A., Price D. L. Lee M. K. (2006) Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41 50.
36. Mayer R. A., Kindt M. V. Heikkila R. E. (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J. Neurochem. 47, 1073 1079.
37. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T. Kagawa Y. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450 1455.
38. Morinan A. Garratt H. M. (1985) An improved fluorimetric assay for brain monoamine oxidase. J. Pharmacol. Methods 13, 213 223.
39. Mouatt-Prigent A., Karlsson J. O., Agid Y. Hirsch E. C. (1996) Increased m-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73, 979 987.
40. Muralikrishnan D., Samantaray S. Mohanakumar K. P. (2003) D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse 50, 7 13.
41. Nicklas W. J., Vyas I. Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503 2508.
42. Parker Jr. W. D., Boyson S. J. Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719 723.
43. Przedborski S. Vila M. (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. 991, 189 198.
44. Przedborski S., Jackson-Lewis V., Naini A. B., Jakowec M., Petzinger G., Miller R. Akram M. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265 1274.
45. Ramsay R. R. Singer T. P. (1986) Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261, 7585 7587.
46. Ray S. K., Wilford G. G., Ali S. F. Banik N. L. (2000a) Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced Parkinson's disease. Ann. NY Acad. Sci. 914, 275 283.
47. Ray S. K., Schaecher K. E., Shields D. C., Hogan E. L. Banik N. L. (2000b) Combined TUNEL and double immunofluorescent labeling for detection of apoptotic mononuclear phagocytes in autoimmune demyelinating disease. Brain Res. 5, 305 311.
48. Reinhard Jr. J. F., Diliberto Jr. E. J., Viveros O. H. Daniels A. J. (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc. Natl Acad. Sci. USA 84, 8160 8164.
49. Russ H., Staust K., Martel F., Gliese M. Schomig E. (1996) The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur. J. Neurosci. 8, 1256 1264.
50. Sage J. I., Kortis H. I. Sommer W. (1990) Evidence for the role of spinal cord systems in Parkinson's disease-associated pain. Clin. Neuropharmacol. 13, 171 174.
51. Samantaray S. Mohanakumar K. P. (2003) Calcium channel agonist, (+/-)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice. Neurosci. Lett. 346, 69 72.
52. Samantaray S., Chandra G. Mohanakumar K. P. (2003) Calcium channel agonist, (+/-)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice. Neurosci. Lett. 342, 73 76.
53. Samantaray S., Ray S. K., Ali S. F. Banik N. L. (2006) Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism. Ann. NY Acad. Sci. 1074, 349 356.
54. Samantaray S., Knaryan V. H., Guyton M. K., Matzelle D. D., Ray S. K. Banik N. L. (2007) The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience 146, 741 755.
55. Sandyk R. Iacono R. P. (1987) Spinal dopamine mechanisms and primary sensory symptoms in Parkinson's disease. Int. J. Neurosci. 32, 927 931.
56. Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B. Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
57. Schneider J. S. Markham C. H. (1986) Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry. Brain Res. 373, 258 267.
58. Speciale S. G., Liang C. L., Sonsalla P. K., Edwards R. H. German D. C. (1998) The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84, 1177 1185.
59. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. Goedert M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839 840.
60. Storch A., Ludolph A. C. Schwarz J. (2004) Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural Transm. 111, 1267 1286.
61. Takada M., Campbell K. J. Hattori T. (1991) Regional localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) uptake: mismatch between its uptake and neurotoxic sites. Neurosci. Lett. 133, 137 140.
62. Wallace R. A., Boldry R., Schmittgen T., Miller D. Uretsky N. (1984) Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. Life Sci. 35, 285 291.
63. Wilson J. S., Turner B. H., Morrow G. D. Hartman P. J. (1987) MPTP produces a mosaic-like pattern of terminal degeneration in the caudate nucleus of dog. Brain Res. 423, 329 332.
64. Xie G. X., Jones K., Peroutka S. J. Palmer P. P. (1998) Detection of mRNAs and alternatively spliced transcripts of dopamine receptors in rat peripheral sensory and sympathetic ganglia. Brain Res. 785, 129 135.